FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

19 letters match. Newest first.

  1. Laboratorios Jaloma S.A. de C.V.

    FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.

    High risk
  2. Intas Pharmaceuticals Limited

    FDA warns Intas Pharmaceuticals' Dehradun, India plant over weak out-of-spec investigations and untracked batch-record edits for its tablets.

    High risk
  3. Persōn & Covey, Inc.

    FDA cites Persōn & Covey for CGMP failures at its Glendale, CA drug plant and for selling unapproved Xerac AC and Drysol.

    High risk
  4. Shiva Analyticals Private Limited

    FDA warned Shiva Analyticals, an Indian contract drug testing lab, that inadequate OOS investigations and data integrity failures adulterated tested drugs.

    High risk
  5. Aspen Pharmacare Holdings Limited

    FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.

    High risk
  6. Applied Therapeutics, Inc.

    Applied Therapeutics, a trial sponsor, failed to let FDA access deleted electronic trial data and omitted dosing-error information from its drug application.

    High risk
  7. Outin Futures Corp.

    FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.

    High risk
  8. GFA Production Xiamen Co., Ltd.

    GFA Production Xiamen failed CGMP for drugs, including process validation, cleaning, and lab controls.

    High risk
  9. Grupo Quimico SRL

    FDA warns Uruguay contract testing lab Grupo Quimico over data integrity failures, including unreported failing HPLC results.

    High risk
  10. Westwood Laboratories LLC

    FDA warned Westwood Laboratories after an inspection found inadequate investigations, raw material testing, lab controls, and water/cleaning controls for OTC drugs.

    High risk
  11. Intas Pharmaceuticals Limited

    FDA warned Intas Pharmaceuticals about serious manufacturing-quality violations, including data integrity failures and inaccurate environmental monitoring, at its India drug plant.

    High risk
  12. Medgel Private Limited

    FDA cited Medgel Private Limited, an Indian OTC drug maker, for manufacturing violations including poor investigations and data integrity failures.

    High risk
  13. Nortec Quimica SA

    FDA warned Brazil's Nortec Quimica, an API maker, over deleted lab data and weak quality unit review of batches exported to the U.S.

    High risk
  14. Colorful Products Corporation

    FDA warned Colorful Products Corporation about serious current good manufacturing practice (CGMP) failures for its over-the-counter topical drugs and hand sanitizers.

    High risk
  15. Vi-Jon, LLC

    FDA cited Vi-Jon for manufacturing-rule violations after finding microbial water contamination, leaks, weak investigations, and data-integrity failures in OTC drugs and cosmetics.

    High risk
  16. Ultra Seal Corporation

    FDA warns Ultra Seal and ULTRAtab over manufacturing quality failures in over-the-counter drug cleaning, testing, and release.

    High risk
  17. Accu Bio-Chem Laboratories

    FDA warned Accu Bio-Chem Laboratories, a contract OTC drug-testing lab, over inadequate failing-result investigations, method verification, and data controls.

    Medium
  18. Adamson Analytical Laboratories, Inc.

    FDA warned California contract drug-testing lab Adamson over inadequate computer controls and data integrity failures.

    High risk
  19. BBC Group Limited

    FDA cites BBC Group Limited for data integrity, lab, equipment failures and unapproved, misbranded hand sanitizers.

    High risk